Xencor (NASDAQ:XNCR) Announces Earnings Results

Xencor (NASDAQ:XNCR) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27, Briefing.com reports. The firm had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business’s revenue for the quarter was down 81.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.40) EPS.

Xencor Price Performance

XNCR stock traded up $0.65 during trading on Thursday, reaching $23.33. 391,213 shares of the company were exchanged, compared to its average volume of 596,344. The company has a 50-day moving average of $20.21 and a two-hundred day moving average of $20.21. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -7.88 and a beta of 0.66. Xencor has a twelve month low of $15.31 and a twelve month high of $26.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on XNCR. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a report on Thursday. BMO Capital Markets reaffirmed an “outperform” rating and set a $32.00 price target on shares of Xencor in a report on Tuesday, August 6th. Royal Bank of Canada upped their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Finally, JPMorgan Chase & Co. upped their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.33.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.